Sort
51,593 grants matching “hepatitis”
Protein Synthesis in Normal and Regenerating Liver
$523,448David A Shafritz · Albert Einstein College Of Medicine · R01 · FY2008 · DK
Optimizing Lung Cancer Treatment in HIV Infected Persons
$523,421Keith Magnus Sigel · Icahn School Of Medicine At Mount Sinai · R01 · FY2019 · CA
Clinical Trial of CNS Penetrating ART to Prevent NeuroAIDS in China
$523,374Scott L Letendre · University Of California, San Diego · R01 · FY2014 · MH
Mechanisms of T Cell Memory Quiescence
$523,322Surojit Sarkar · Seattle Children'S Hospital · R01 · FY2020 · AI
Mechanisms of T Cell Memory Quiescence
$523,322Surojit Sarkar · Seattle Children'S Hospital · R01 · FY2019 · AI
Behavioral Drug and HIV Risk Reduction Counseling with MMT in China
$523,316Marek C Chawarski · Yale University · R01 · FY2011 · DA
HCV-specific T cell response
$523,271Christopher M. Walker · Research Inst Nationwide Children'S Hosp · R37 · FY2007 · AI
Mechanisms of Insulin Resistance in Man
$523,266Robert A. Rizza · Mayo Clinic Rochester · R01 · FY2006 · DK
Drug Resistance in HCV NS3/4A - Inhibitor binding versus substrate recognition
$523,252Celia A. Schiffer · Univ Of Massachusetts Med Sch Worcester · R01 · FY2016 · AI
Acute and Chronic In vivo Effects of Engineered Nanomaterials
$523,250Terry Gordon · New York University School Of Medicine · U01 · FY2012 · ES
Optimal Long-term Outcome of Chronic Hepatitis B
$523,159W. Ray Kim · Mayo Clinic Rochester · U01 · FY2010 · DK
Increasing Hep B screening among Korean church attendees
$523,130Roshan Bastani · University Of California At Davis · P01 · FY2008 · CA
NIH-Owned Chimpanzee Research Resource at the SNPRC
$523,117John L Vandeberg · Texas Biomedical Research Institute · U42 · FY2012 · OD
Mechanisms of hepatic innate immune activation by HCV
$523,114Michael J Gale · University Of Washington · R01 · FY2021 · AI
Mechanisms of hepatic innate immune activation by HCV
$523,114Michael J Gale · University Of Washington · R01 · FY2020 · AI
Sphingolipids in alcoholic liver disease
$523,062Huiping Rose Zhou · Virginia Commonwealth University · R01 · FY2024 · AA
Sphingolipids in alcoholic liver disease
$523,062Huiping Rose Zhou · Virginia Commonwealth University · R01 · FY2025 · AA
Sphingolipids in alcoholic liver disease
$523,062Huiping Rose Zhou · Virginia Commonwealth University · R01 · FY2023 · AA
MANAGEMENT OF THE HEPATITIS C OUTBREAK IN SOUTHERN NEVADA
$523,000Deborah Williams · Southern Nevada Health District · H75 · FY2009 · PS
Mechanisms of Insulin Resistance in Man
$522,996Robert A. Rizza · Mayo Clinic Rochester · R01 · FY2007 · DK
In Situ Albumin Binding siRNAs for Triple Negative Breast Cancer Tumor Penetration and Molecularly Targeted Therapy
$522,993Craig Lewis Duvall · Vanderbilt University · R01 · FY2024 · CA
Restoration of Innate Immunity with Viral Cure
$522,953Raymond T Chung · Massachusetts General Hospital · U19 · FY2017 · AI
Endovascular Chemofiltration: Optimizing Removal of Chemotherapeutics and Nanoparticles from the Blood to Reduce Toxicity
$522,926Steven William Hetts · University Of California, San Francisco · R01 · FY2016 · CA
HIV, HCV and Liver Disease Among Injection Drug Users in Chennai, India
$522,913Shruti H Mehta · Johns Hopkins University · R01 · FY2015 · DA
4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN): A Phase II Clinica
$522,886Lee Roy Morgan · Dekk-Tec, Inc. · R44 · FY2014 · CA